Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push
The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Viatris to make $1.65B Pacira acquisition, adding to momentum in pain endpoints.news
- Viatris boosts pain drug portfolio with $1.7B buyout of Pacira biopharmadive.com
